Ligand-directed serotonin 5-HT 2C receptor desensitization and sensitization

Daniel Felsing, Clinton E. Canal, Raymond G. Booth

Research output: Contribution to journalArticle

Abstract

Exposure of G protein–coupled receptors (GPCRs) to agonists can desensitize receptor signaling and lead to drug tolerance, whereas inverse agonists can sensitize signaling. For example, activation of serotonin 5-HT 2C GPCRs is pharmacotherapeutic for obesity, but there is tolerance to the anorectic effect of the only approved 5-HT 2C agonist, lorcaserin. We tested the hypothesis that different agonists or inverse agonists differentially desensitize or sensitize, respectively, canonical 5-HT 2C -mediated activation of phospholipase C (PLC) signaling in vitro. Lorcaserin, which displays potency and efficacy equal to 5-HT, desensitized the 5-HT 2C receptor significantly more than 5-HT (p<0.05). Agonist chemotypes such as 2-aminotetralins, with similar potency but lower efficacy than 5-HT, produced little 5-HT 2C desensitization. The piperazine agonist 1-(3-chlorophenyl)piperazine (mCPP), with lower potency but similar efficacy as 5-HT, elicited desensitization indistinguishable from 5-HT, while the piperazine agonist aripiprazole, with lower potency and efficacy, did not desensitize 5-HT 2C -PLC signaling. Several 5-HT 2C agonists also were assessed for β-arrestin recruitment—lorcaserin was a ‘super-agonist’ but a 2-aminotetralin and aripiprazole had nil activity, suggesting they are biased towards 5-HT 2C -PLC signaling. We observed robust positive correlations between the magnitude of 5-HT 2C desensitization and agonist efficacy to stimulate PLC or to recruit β-arrestin. In contrast, different inverse agonists caused different magnitudes of 5-HT 2C  sensitization that did not correlate with efficacy (or potency) to inhibit constitutive 5-HT 2C -PLC signaling.  Assessment of the 5-HT 2C -S407A point-mutated receptor indicated this residue's involvement in ligand-dependent desensitization, but we did not observe a role for protein kinase C.These data show that ligand structure uniquely impacts 5-HT 2C desensitization and sensitization processes.

Original languageEnglish (US)
Pages (from-to)131-139
Number of pages9
JournalEuropean Journal of Pharmacology
DOIs
StatePublished - Apr 5 2019
Externally publishedYes

Fingerprint

Receptor, Serotonin, 5-HT2C
Serotonin
Ligands
Type C Phospholipases
Serotonin Receptor Agonists
Arrestin
Drug Tolerance
Appetite Depressants

Keywords

  • 5-HT receptor
  • Aminotetralin
  • Desensitization
  • phospholipase C
  • Sensitization
  • β-arrestin

ASJC Scopus subject areas

  • Pharmacology

Cite this

Ligand-directed serotonin 5-HT 2C receptor desensitization and sensitization . / Felsing, Daniel; Canal, Clinton E.; Booth, Raymond G.

In: European Journal of Pharmacology, 05.04.2019, p. 131-139.

Research output: Contribution to journalArticle

@article{e5ce6b83c40f4af6b1d986d56c189196,
title = "Ligand-directed serotonin 5-HT 2C receptor desensitization and sensitization",
abstract = "Exposure of G protein–coupled receptors (GPCRs) to agonists can desensitize receptor signaling and lead to drug tolerance, whereas inverse agonists can sensitize signaling. For example, activation of serotonin 5-HT 2C GPCRs is pharmacotherapeutic for obesity, but there is tolerance to the anorectic effect of the only approved 5-HT 2C agonist, lorcaserin. We tested the hypothesis that different agonists or inverse agonists differentially desensitize or sensitize, respectively, canonical 5-HT 2C -mediated activation of phospholipase C (PLC) signaling in vitro. Lorcaserin, which displays potency and efficacy equal to 5-HT, desensitized the 5-HT 2C receptor significantly more than 5-HT (p<0.05). Agonist chemotypes such as 2-aminotetralins, with similar potency but lower efficacy than 5-HT, produced little 5-HT 2C desensitization. The piperazine agonist 1-(3-chlorophenyl)piperazine (mCPP), with lower potency but similar efficacy as 5-HT, elicited desensitization indistinguishable from 5-HT, while the piperazine agonist aripiprazole, with lower potency and efficacy, did not desensitize 5-HT 2C -PLC signaling. Several 5-HT 2C agonists also were assessed for β-arrestin recruitment—lorcaserin was a ‘super-agonist’ but a 2-aminotetralin and aripiprazole had nil activity, suggesting they are biased towards 5-HT 2C -PLC signaling. We observed robust positive correlations between the magnitude of 5-HT 2C desensitization and agonist efficacy to stimulate PLC or to recruit β-arrestin. In contrast, different inverse agonists caused different magnitudes of 5-HT 2C  sensitization that did not correlate with efficacy (or potency) to inhibit constitutive 5-HT 2C -PLC signaling.  Assessment of the 5-HT 2C -S407A point-mutated receptor indicated this residue's involvement in ligand-dependent desensitization, but we did not observe a role for protein kinase C.These data show that ligand structure uniquely impacts 5-HT 2C desensitization and sensitization processes.",
keywords = "5-HT receptor, Aminotetralin, Desensitization, phospholipase C, Sensitization, β-arrestin",
author = "Daniel Felsing and Canal, {Clinton E.} and Booth, {Raymond G.}",
year = "2019",
month = "4",
day = "5",
doi = "10.1016/j.ejphar.2019.01.037",
language = "English (US)",
pages = "131--139",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - Ligand-directed serotonin 5-HT 2C receptor desensitization and sensitization

AU - Felsing, Daniel

AU - Canal, Clinton E.

AU - Booth, Raymond G.

PY - 2019/4/5

Y1 - 2019/4/5

N2 - Exposure of G protein–coupled receptors (GPCRs) to agonists can desensitize receptor signaling and lead to drug tolerance, whereas inverse agonists can sensitize signaling. For example, activation of serotonin 5-HT 2C GPCRs is pharmacotherapeutic for obesity, but there is tolerance to the anorectic effect of the only approved 5-HT 2C agonist, lorcaserin. We tested the hypothesis that different agonists or inverse agonists differentially desensitize or sensitize, respectively, canonical 5-HT 2C -mediated activation of phospholipase C (PLC) signaling in vitro. Lorcaserin, which displays potency and efficacy equal to 5-HT, desensitized the 5-HT 2C receptor significantly more than 5-HT (p<0.05). Agonist chemotypes such as 2-aminotetralins, with similar potency but lower efficacy than 5-HT, produced little 5-HT 2C desensitization. The piperazine agonist 1-(3-chlorophenyl)piperazine (mCPP), with lower potency but similar efficacy as 5-HT, elicited desensitization indistinguishable from 5-HT, while the piperazine agonist aripiprazole, with lower potency and efficacy, did not desensitize 5-HT 2C -PLC signaling. Several 5-HT 2C agonists also were assessed for β-arrestin recruitment—lorcaserin was a ‘super-agonist’ but a 2-aminotetralin and aripiprazole had nil activity, suggesting they are biased towards 5-HT 2C -PLC signaling. We observed robust positive correlations between the magnitude of 5-HT 2C desensitization and agonist efficacy to stimulate PLC or to recruit β-arrestin. In contrast, different inverse agonists caused different magnitudes of 5-HT 2C  sensitization that did not correlate with efficacy (or potency) to inhibit constitutive 5-HT 2C -PLC signaling.  Assessment of the 5-HT 2C -S407A point-mutated receptor indicated this residue's involvement in ligand-dependent desensitization, but we did not observe a role for protein kinase C.These data show that ligand structure uniquely impacts 5-HT 2C desensitization and sensitization processes.

AB - Exposure of G protein–coupled receptors (GPCRs) to agonists can desensitize receptor signaling and lead to drug tolerance, whereas inverse agonists can sensitize signaling. For example, activation of serotonin 5-HT 2C GPCRs is pharmacotherapeutic for obesity, but there is tolerance to the anorectic effect of the only approved 5-HT 2C agonist, lorcaserin. We tested the hypothesis that different agonists or inverse agonists differentially desensitize or sensitize, respectively, canonical 5-HT 2C -mediated activation of phospholipase C (PLC) signaling in vitro. Lorcaserin, which displays potency and efficacy equal to 5-HT, desensitized the 5-HT 2C receptor significantly more than 5-HT (p<0.05). Agonist chemotypes such as 2-aminotetralins, with similar potency but lower efficacy than 5-HT, produced little 5-HT 2C desensitization. The piperazine agonist 1-(3-chlorophenyl)piperazine (mCPP), with lower potency but similar efficacy as 5-HT, elicited desensitization indistinguishable from 5-HT, while the piperazine agonist aripiprazole, with lower potency and efficacy, did not desensitize 5-HT 2C -PLC signaling. Several 5-HT 2C agonists also were assessed for β-arrestin recruitment—lorcaserin was a ‘super-agonist’ but a 2-aminotetralin and aripiprazole had nil activity, suggesting they are biased towards 5-HT 2C -PLC signaling. We observed robust positive correlations between the magnitude of 5-HT 2C desensitization and agonist efficacy to stimulate PLC or to recruit β-arrestin. In contrast, different inverse agonists caused different magnitudes of 5-HT 2C  sensitization that did not correlate with efficacy (or potency) to inhibit constitutive 5-HT 2C -PLC signaling.  Assessment of the 5-HT 2C -S407A point-mutated receptor indicated this residue's involvement in ligand-dependent desensitization, but we did not observe a role for protein kinase C.These data show that ligand structure uniquely impacts 5-HT 2C desensitization and sensitization processes.

KW - 5-HT receptor

KW - Aminotetralin

KW - Desensitization

KW - phospholipase C

KW - Sensitization

KW - β-arrestin

UR - http://www.scopus.com/inward/record.url?scp=85061227611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061227611&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2019.01.037

DO - 10.1016/j.ejphar.2019.01.037

M3 - Article

SP - 131

EP - 139

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -